Anti-CD19 CAR-T cells are the most effective in fatal relapsed/refractory B-cell acute lymphoblastic leukaemia (B-ALL) treatment [10,91]. This evidence concerns the gene CD19 and precursor B-cell acute lymphoblastic leukemia.